- Home
- INO vs NRXP Comparison
INO vs NRXP Comparison
Compare INO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INO | NRXP |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 99.2M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | INO | NRXP |
|---|---|---|
| Price | $1.18 | $4.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.75 | ★ $38.25 |
| AVG Volume (30 Days) | ★ 3.7M | 1.5M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,220,086.00 | N/A |
| Revenue This Year | $20,156.19 | $2,547.84 |
| Revenue Next Year | $421.95 | $1,591.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $1.03 | $1.65 |
| 52 Week High | $2.86 | $5.06 |
Technical Indicators
Market Signals| Indicator | INO | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 62.03 |
| Support Level | $1.03 | $1.89 |
| Resistance Level | $1.23 | N/A |
| Average True Range (ATR) | 0.10 | 0.43 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 12.50 | 55.81 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.